400 Participants Needed

Screening for Amyloidosis in Multiple Myeloma

Recruiting at 15 trial locations
DT
RC
Overseen ByRaymond Comenzo, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Tufts Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to detect light-chain amyloidosis (AL), a condition where proteins accumulate in organs, in individuals with smoldering multiple myeloma (SMM) before symptoms appear. Researchers seek to develop a tool to predict the likelihood of this condition. Participants must be at least 40 years old and diagnosed with SMM or a related condition called monoclonal gammopathy, with specific protein levels in their blood. This study targets those who do not currently require treatment for their condition. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could lead to early detection tools for AL.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to detect AL Amyloidosis early in patients with smoldering multiple myeloma. Unlike traditional approaches that focus on treating symptoms after they appear, this trial explores the potential to identify and manage the condition before it progresses. Early detection could lead to more timely interventions, potentially improving outcomes and quality of life for patients. By focusing on screening, this study could pave the way for preventive strategies that are more effective than current reactive treatments.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 40 years old or older.
I have been diagnosed with Smoldering Multiple Myeloma.
My blood test shows an abnormal protein level.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Collection of marrow and blood specimens, evaluation of clinical marrow specimens, and processing by NGS for clonal IGLV gene identification

5 years

Algorithm Development

Using collected data to generate a statistical algorithm for identifying undiagnosed cases of AL and assessment of risk of AL

5 years

Follow-up

Participants are monitored for safety and effectiveness after data collection and algorithm development

6 months

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Tufts Medical Center

Lead Sponsor

Trials
264
Recruited
264,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+